Focus: Vaxart is a public biotech company pioneering oral vaccine delivery for infectious diseases including influenza, RSV, COVID-19, and norovirus. The company operates at pre-commercial stage with a diversified pipeline but minimal near-term revenue.
Profile data last refreshed 15h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
Vaxart offers high-risk/high-reward opportunity for scientists committed to novel vaccine modalities, but significant clinical validation and financial execution risks exist before career stability materializes.
Lead Phase 2 RSV program; oral delivery addresses major unmet need in respiratory vaccines.
Help build intelligence for Vaxart
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vaxart's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Phase 2 COVID oral vaccine capitalizes on post-pandemic booster demand and mucosal immunity differentiation.
Phase 2 oral influenza vaccine targets $4B+ annual vaccine market with potential convenience advantage over injections.
Vaxart (OTCQX: VXRT) outlines 2025 governance, pay and ownership - Stock Titan
Vaxart (OTCQX: VXRT) outlines 2025 governance, pay and ownership Stock Titan
Biotech leader James Breitmeyer joins Vaxart (VXRT) board, boosting clinical expertise - Stock Titan
Biotech leader James Breitmeyer joins Vaxart (VXRT) board, boosting clinical expertise Stock Titan
Vaxart Expands Utah Avenue Space, Consolidates South SF Footprint - The Globe and Mail
Vaxart Expands Utah Avenue Space, Consolidates South SF Footprint The Globe and Mail
Armistice Head Testifies He Accidentally Deleted Texts - Law360
Armistice Head Testifies He Accidentally Deleted Texts Law360
Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told - Law360
Armistice Capital Used COVID To Juice Vaxart Stock, Jury Told Law360
Altesa, run by former Trump official, raises $75M for well-traveled lung drug - BioPharma Dive
Altesa, run by former Trump official, raises $75M for well-traveled lung drug BioPharma Dive
Showing 6 of 8 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo